Reported Sunday, Taiho And Cullinan's Zipalertinib Shows 40% ORR In Platinum-Treated EGFR ex20ins NSCLC, REZILIENT1 Results Published In JCO

Author: Benzinga Newsdesk | June 02, 2025 03:31am

Highlights of the REZILIENT1 Phase 1/2 trial in the authors' conclusions include:

• Zipalertinib demonstrated clinically meaningful efficacy in the primary efficacy population (n=176), including 51 patients who had received prior amivantamab.
• The confirmed objective response rate (ORR) was 35.2% overall, and median duration of response (mDOR) and progression-free survival were 8.8 months and 9.4 months, respectively.
• In patients treated after prior platinum-based chemotherapy only (n=125), ORR was 40% with mDOR of 8.8 months.
• The safety profile of zipalertinib was manageable and consistent with previously reported data.¹
• In exploratory subgroup analyses:
  • Patients who had received prior amivantamab without other ex20ins-targeted therapy showed a confirmed ORR of 30% and mDOR of 14.7 months.
  • Patients with brain metastases showed a confirmed ORR of 30.9% and a mDOR of 8.3 months

Posted In: CGEM TAIHF